drugset / Trial / NCT02580708

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT02580708

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.

Timeline

Start
2015-09-30
Primary completion
2016-05-05
Completion
2016-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Rociletinib Small molecule
Subject Trametinib Small molecule